natgillin/translations-raw huggingface dataset:
Compounds according to claim 1 wherein R4 represents an optionally substituted linear or branched (C1-C6)alkoxy group or a -O-alkyl(C1-C6)-R9 group. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da R4 predstavlja po izboru supstituiranu ravnu ili razgrananu (C1-C6)alkoksi skupinu ili -O-alkil(C1-C6)-R9 skupinu.
In one embodiment, the method is combined with one or more other methods for estimating the perception quality of a digital video by compression and/or transmission, wherein the combination is preferably performed using at least a linear function and/or at least a multiplicative function of the methods to be combined. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se postupak kombinira s jednim ili više drugih postupaka procjenjivanja kvalitete percepcije digitalnog videa kompresijom i/ili prijenosom, gdje se kombiniranje po mogućnosti provodi uz upotrebu u najmanju ruku linearne funkcije i/ili u najmanju ruku funkcije množenja u postupcima koje treba kombinirati.
Method of wrapping smoking article rods, in particular in the production of cigars, with a wrapper, including the steps: 
Postupak omatanja omotom šipki od proizvoda za pušenje, naročito u proizvodnji cigara, koji postupak sadržava sljedeće korake:
A compound for use as claimed in claim 1 to 4 wherein when R3 is F, R3 is in position ortho of the aromatic ring and R4 is F in position para of the aromatic ring. 
Spoj za upotrebu prema patentnom zahtjevu 1 do 4 naznačen time što kada je R3 jednako F, R3 je u orto položaju aromatičnog prstena 1 Ry je F u para položaju aromatičnog prstena.
An inhaler according to claim 12, wherein said medicament is dissolved in said propellant or said medicament is suspended in said propellant. 
Inhalator u skladu s patentnim zahtjevom 6, pri čemu inhalator nadalje obuhvaća spremnik lijeka koji je pod tlakom i koji sadrži lijek i propelant, poželjno je navedeni lijek otopljen u navedenom propelantu ili je navedeni lijek suspendiran u navedenom propelantu.
1, which may include a plurality of processors). In another example, the form may be selected from the group consisting of: a lottery play slip; a survey; and a test. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se formular (400, 700) bira iz skupine koju čine: lutrijski listić; anketa; i test.
An electronic device with an air cleaner according to claim 8, wherein the electronic device is an entertainment, gambling and/or betting machine with a machine housing, and wherein the filter module is provided at or on the inside of the machine housing. 
Elektronički uređaj s pročistačem zraka sukladno jednom od zahtjeva 9 do 15, osobito uređaj za zabavu, kockanje i/ili klađenje s kućištem stroja, pri čemu je pročistač zraka smješten na ili unutar kućišta stroja.
formula (II) (stem-loop sequence with stem bordering elements): wherein: 
peteljka2 formula (II) (peteljka-omča sekvenca sa graničnim elementima peteljke):
A compound of formula 7 wherein P is a protecting group such as acetyl. 
HR P20150879 T1 Pri čemu je P zaštitna grupa kao što je acetil.
The method of claim 1, wherein, when the available intra prediction mode is a planar mode, the two additional intra prediction modes include a DC mode and the vertical mode. 
Metoda prema zahtjevu 1, naznačena time da je dostupni unutarokovirni načina predviđanja planarni način, dva dodatna unutarokovirna načina predviđanja su DC način i vertikalni način.
A method as claimed in claim 12 characterised in that the non-woven web is made by hydroentangling a web of Lyocell fibres and carboxymethylating the so formed web. 
Postupak prema zahtjevu 12 naznačen time što se netkana traka izrađuje hidrouplitanjem trake od Lyocell vlakana i karboksimetilacijom tako formirane trake.
The capsule according to claim 2, wherein the annular projection, in section, has a thickness decreasing downwards. 
Kapsula u skladu s patentnim zahtjevom 1 i / ili 2, naznačena time, da navedeno ispupčenje (16), u presjeku, ima debljinu koja se smanjuje prema dolje.
Panel according to any of the claims 12 to 16 having a thickness swelling ranging from 7% to 8% after 24 hours of immersion in water, said swelling being measured in a panel having a thickness of 20 millimetres. 
Ploča u skladu s bilo kojim od patentnih zahtjeva 12 do 16, naznačena time, da nakon 24-satne uronjenosti u vodi nabubri u rasponu od 7 % do 8 %, pri čemu se navedeno bubrenje mjeri u ploči debljine 20 milimetara.
A pharmaceutical composition for delivery of one or more encapsulated polynucleotides to one or more target cells, said composition comprising an mRNA as a first encapsulated polynucleotide and a blend of at least a first lipid nanoparticle and a second lipid nanoparticle, wherein the first lipid nanoparticle encapsulates the mRNA; and wherein the first lipid nanoparticle comprises at least one lipid distinct from the second lipid nanoparticle. 
Farmaceutski pripravak za isporuku polinukleotida tipa informacijske RNK (iRNK) do jedne ili više ciljnih stanica, naznačen time da navedeni pripravak sadrži iRNK i mješavinu najmanje prve lipidne nanočestice 1 druge lipidne nanočestice, pri čemu prva lipidna nanočestica sadrži iRNK; 1 pri čemu prva lipidna nanočestica sadrži najmanje jedan lipid jasno različit od druge lipidne nanočestice.
A conjugate comprising a fusion protein to transport a brain effector entity across the blood brain barrier of claims 21 to 25 and a brain effector entity coupled to a N-terminal end of the CH2-CH3 Ig entity of the fusion protein by a linker. 
Konjugat, naznačen time, da obuhvaća fuzijski protem za prijenos entiteta moždanog efektora preko moždano-krvne barijere prema zahtjevima 18 ili 19, te entitet moždanog efektora spojen s N-terminalnim krajem entiteta CH2-CH2-Ig od fuzijskog proteina putem povezivača.
A method according to any one of the preceding claims, wherein the message is selected from group consisting of: a message of short messaging service; multimedia messaging service; picture messaging service; and mobile instant messaging service. 
Postupak prema bilo kojem od prethodnih zahtjeva, gdje se poruka odabire iz grupe koja obuhvaća: poruku iz usluge kratkih poruka; uslugu multimedijalnih poruka; uslugu slanja slika; 1 uslugu mobilnih instant poruka.
A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier or diluent. 
Farmaceutski sastav, naznačen time, da sadrži spoj prema bilo kojem od zahtjeva 1 do 25, te farmaceutski prihvatljiv nosač ili razrjeđivač.
The intravaginal ring of claim 1, wherein the intravaginal ring comprises: 
Monolitni intravaginalni prsten u skladu s patentnim zahtjevom 1, naznačen time, da intravaginalni prsten sadrži:
Excessive drying or exposure to air can also reduce the efficacy of the biological ingredient. 
Pretjerano sušenje ili izlaganje zraku može isto tako umanjiti djelotvornost biološkog sastojka.
The compound of claim 1, having Formula (IV): 
Spoj iz patentnog zahtjeva 5, koje ima formulu (IV):
The solid dosage form of claim 2 wherein the polymorphic crystalline form of a compound of Formula I is present from about 75% to about 99.99% of the total weight of tiacumicins. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je polimorf Formule I prisutan u od 75% do 99,99% od ukupne težine, te gdje je farmaceutski pripravak u čvrstom obliku doziranja.
Use according to claim 12, characterized in that said antibiotic or other antimicrobial agent is selected from aminoglycosides, tetracyclines, macrolides, quinolones, sulfonamides alone or combined with diaminopyridines, penicilline compounds, cephalosporins and other B-lactam antibiotics, lincosamides, antiprotozoarians, antibacterials, antiseptics and salts thereof. 
Upotreba u skladu s patentnim zahtjevom 12, naznačena time što navedeni antibiotik ili antimikrobno sredstvo so bira između aminoglikozida, tetraciklina, makrolida, kinolona, sulfonamida samih ili u kombinaciji s diaminopiridinima, penicilinskih spojeva, cefalosporina i drugih B-laktamskih antibiotika, linkozamida, antiprotozoika, antibakterijskih sredstava, antiseptika i njihovih soli.
The method of claim 9, wherein said viral vector is replication-competent. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što je navedeni virusni vektor replikacijski kompetentan.
The composition for use of claim 7 or claim 9, wherein the therapeutic agent is insulin or a recombinant insulin. 
Pripravak za uporabu u skladu s patentnim zahtjevom 7 ili zahtjevom 9, naznačen time, da je terapijsko sredstvo inzulin ili rekombinantni inzulin.
Use according to claims 9 or 12, characterised In that the maximum dose of fentanyl per treatment does not exceeds 200 mcg/patient. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno bilo kojem od zahtjeva 1 do 5 i 8, naznačen time što maksimalna doza fentanila po tretmanu ne prelazi 200 meg/pacijentu.
The pharmaceutical composition in form of emulsion or microemulsion according to claim 10, wherein said at least one lipophilic compound is selected from natural oils, such as almond oil, canola oil, castor oil, corn oil, cottonseed oil, olive oil, safflower oil, sesame oil, soybean oil; fatty acid esters, such as isopropyl palmitate, isopropyl myristate, ethyl oleate; fatty alcohols, such as myristic alcohol, oleyl alcohol; fatty acids, such as myristic acid, oleyl acid, palmitic acid, triglycerides, such as long and/or medium-chain triglycerides; diglycerides and monoglycerides. 
Farmaceutski pripravak u obliku emulzije ili mikroemulzije prema zahtjevu 10, gdje se taj barem jedan lipofilni spoj odabire između prirodnih ulja, kao što su bademovo ulje, kanola ulje, ricinusovo ulje, kukuruzno ulje, pamučno ulje, maslinovo ulje, ulje šafranike, sezamovo ulje, sojino ulje; estera masnih kiselina, kao što su izopropil palmitat, izopropil miristat, etil oleat; masnih alkohola, kao što su miristinski alkohol, oleinski alkohol; masnih kiselina, kao što su miristinska kiselina, oleinska kiselina, palmitinska kiselina; triglicerida, kao što su dugolančani i/ili srednjelančani trigliceridi; diglicerida 1 monoglicerida.
providing milk at about 2,3 bar, with a flow rate of about 10 to 12 tons/h, at about 55°C, 
pribavljanje mlijeka pod tlakom od oko 2,3 bara, brzinom protoka od 10 do 12 tona/h, temperature oko 55 °C,
Coating composition according to claim 1 or 2, characterised in that said SNGCC has a median diameter (d50 (Mal)) of between 0.1 and 0.3 µm. 
Sastav za oblaganje u skladu s patentnim zahtjevom 1 ili 2, karakteriziran na način da navedeni SNGCC ima srednji promjer (d50 (Mal)) između 0.1 i 0.3 µm.
is tert-butyl; is selected from the group consisting of hydrogen, hydroxy, methoxy, and halo; 
R* je tert-butil: i R> je odabran iz skupine koja sadrži hidroksi i metoksi.
A compound, or a pharmaceutically acceptable salt thereof, of claims 1-8, or a pharmaceutical composition of claim 9 or claim 10, for use according to claim 11, wherein the disorder is cancer selected from leukemia, lymphoma, thymus, brain, lung, squamous cell, skin, eye, retinoblastoma, intraocular melanoma, oral cavity and oropharyngeal, bladder, gastric, stomach, pancreatic, bladder, breast, cervical, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, esophageal, testicular, gynecological, thyroid, CNS, PNS, AIDS-related cancer, Kaposi's Sarcoma, mastocytosis, and viral-induced cancer. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak u skladu s patentnim zahtjevom 4, namijenjeni upotrebi u skladu s patentnim zahtjevom 7, naznačeni time što se rak bira između raka timusa, mozga, pluća, pločastih stanica, kože, oka, retinoblastoma, intraokularnog melanoma, raka usne šupljine i orofarinksa, mokraćnog mjehura, želučanog raka, raka želuca, gušterače, mokraćnog mjehura, dojke, vrata maternice, glave, vrata, bubrežnog raka, raka bubreg, jetre, jajnika, prostate, kolorektalnog raka, raka jednjaka, testisa, ginekološkog raka, raka štitnjače, CNS-a, PNSa, raka povezanog s AIDS-om, Kaposijevog sarkoma i raka uzrokovanog virusima.
said furin or furin derivative from a protein solution is bound to a cation exchange resin with a potential to bind furin at pH 6.0, and is recovered by elution. 
(A) vezanje navedenog furin polipeptida ili skraćenog furin polipeptida sa mješavinom smole za kationsku izmjenu / hidrofobnu interakciju s potencijalom da veže furin polipeptid ili skraćeni furin polipeptid pri pH 6.0, 1
In a ninth aspect, the invention features a composition according to the first or second aspect wherein said selective 5HT-2C receptor agonist is selected from the group consisting of: 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; 8-bromo-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; 
Pripravak u skladu sa zahtjevom 1, naznačen time, da je navedeni selektivni agonist SHT-2C receptora izabran iz skupine koju čine slijedeći spojevi i njihove farmaceutski prihvatljive soli, solvati i hidrati: 8-kloro-1-metil-2,3,4,5-tetrahididro-1H-3-benzazepin; 8-bromo-1-metil-2,3,4,5-tetrahididro-1H-3-benzazepin;
In one embodiment, provided is Compound—3 that is a 19-mer double-stranded nucleic acid molecule wherein the sense strand is SEQ ID NO:98 and includes 2′-5′-ribonucleotides in positions 15, 16, 17, 18, and 19; a C3-OH 3′ moiety covalently attached at the 3′-terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5′-terminus; and the antisense strand is SEQ ID NO:165 and includes 2′OMe modified ribonucleotides in positions 2, 4, 6, 8, 11, 13, 15, 17, and 19; a 2′-5′-ribonucleotide in position 7; and a C3Pi-C3OH covalently attached at the 3′-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što smisleni lanac sadrži SEQ ID NO:98, a protusmisleni lanac sadrži SEQ ID NO:165; gdje smisleni lanac dodatno sadrži 2'-5'- ribonukleotide na položajima 15, 16, 17, 18, te 19; C3-OH 3' ostatak kovalentno vezan na 3'-kraju; i invertirani nebazni deoksiribonukleotidni ostatak kovalentno vezan na 5'-kraju; i gdje protusmisleni lanac dodatno sadrži 2'- O-metilom modificirane ribonukleotide na položajima 2, 4, 6, 8, 11, 13, 15, 17, te 19; 2'-5'-ribonukleotid na položaju 7; i C3Pi-C30H ostatak kovalentno vezan na 3'-kraju.
A method as claimed in any one of claims 14 to 19, wherein the additive composition does not comprise a 'nitrogen containing compound' nor 'an halide compound'. 
Metoda temeljem bilo kojeg od zahtjeva 14 do 19, naznačena time što sastav aditiva ne uključuje "spoj koji sadrži dušik" niti "spoj halida".
The compound according to claim 1, wherein R1 represents an aromatic group which can be substituted, Ring A represents an aromatic ring which is substituted with 
predstavlja aromatsku skupinu koja može biti supstituirana; Prsten A predstavlja aromatski prsten koji može biti supstituiran sa sljedećima:
contacting a 0 protein-coupled receptor with an optionally labeled known ligand to the receptor in the presence or absence of a test compound, wherein the G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of: amino acids 1-335 of SEQ ID NO:2; amino acids 2-335 of SEQ ID NO:2; 
(x) stavljanje u doticaj test spoja sa stanicom domačina ili s membranom stanice domaćina, koji sadrži receptor vezanih G-proteina, pri čemu receptor vezanih G-proteina sadrži sekvencu amino kiseline odabranu iz skupine koja sadrži: (i) amino kiseline 1-335 od SEQ ID NO:2; (ii) amino kiseline 2-335 od SEQ ID NO:2;
is hydrogen, chloro, cyclopropyl, or C1-4 aliphatic, optionally substituted with 1-3 fluorine atoms. 
R> je vodik, kloro, ciklopropil ili C,_4 alifatik, izborno supstituiran sa 1-3 atoma fluora.
The method is characterized in that a therapeutically effective and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is administered to the mammal with the disease, with the active pharmaceutical ingredient being administered in a pharmaceutical preparation of the invention. 
Postupak je okarakteriziran time da se terapeutski učinkovita 1 farmakološki prikladna količina aktivnog farmaceutskog sastojka izabrana iz skupine spojeva roflumilasta, soli roflumilasta, N-oksida roflumilasta 1 njegovih soli, primijeni sisavcu s bolesti, pri čemu se aktivni farmaceutski sastojak primjenjuje u farmaceutskom pripravku izuma.
In another aspect of the invention, particular compounds of the invention are selected from: 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (2R)-2,4-dimethylpiperazine-1-carboxylate; 
Spojevi formule (I) prema patentnom zahtjevu 1 koje je 4-[(3-kloro-2-fluorofeniljamino]-7-metoksikinazolin-6-il (2R)-2,4-dimetilpiperazin-1-karboksilat.
A method for inducing an immunogenic or protective response in an animal against one or more avian pathogens comprising at least one administration of the composition or vector of any one of paragraphs 1-30. 
Vektor prema zahtjevu 10, naznačen time, da se upotrebljava u postupku induciranja imunosnog ili zaštitnog odgovora kod životinje protiv jednog ili više ptičjih patogena, pri čemu navedeni postupak obuhvaća najmanje jednu primjenu spomenutog sastava ili cjepiva.
The features and advantages of a recoil damper system according to this invention will be more evident in the following description, which is by way of example only and not restrictive, in reference to the enclosed diagrams in which: 
Karakteristike i prednosti sustava za prigušivanje trzanja koji su u skladu s ovim izumom, biti će vidljivi u opisu koji slijedi i koji je prikazan kao primjer i ne ograničava ova ovaj izum na taj prikaz, pri čemu se vrši pozivanje na priložene crteža koji prikazuju sljedeće: sika 1
The composition of claim 7, wherein the adjuvant is selected from the group consisting of an oil-in-water adjuvant, a polymer and water adjuvant, a water-in-oil adjuvant, an aluminum hydroxide adjuvant, a vitamin E adjuvant and combinations thereof. 
Pripravak u skladu s patentnim zahtjevom 7, naznačen time što se adjuvans bira iz skupine koju čine ulje u vodi kao adjuvans, polimer i voda kao adjuvans, voda u ulju adjuvans, aluminijev hidroksid kao adjuvans, vitamin E kao adjuvans i njihove kombinacije.
A compound of claim 5 wherein R3 is chlorine. A compound of claim 6 having the general formula (II) 
Formulacija za inhaliranje bez propelanta koja sadrži spoj opće formule (II) kako je definiran u patentnom zahtjevu 1.
The method of claim 4, wherein the hydrogen donor is formic acid; or wherein optionally the molar ratio of formic acid versus 3-(2-methyl-5-nitro-4-oxoquinazolin-3(4 H)-yl)piperidine-2,6-dione is ranging from about 1 to about 100, or is ranging from about 15 to about 25. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što je donor vodika mravlja kiselina; ili gdje se molarni omjer između mravlje kiseline 1 3-(2-metil-5-nitro-4-oksokinazolin-3(4H)-il)piperidin-2,6-diona može kretati u rasponu od otprilike 1 do otprilike 100, ili se može kretati u rasponu od otprilike 15 do otprilike 25.
inserting the partly CX-REED treated liquid into the chamber for the AX-REED liquid 
VI. ubacivanje djelomično obrađene tekućine s AX-REED u komoru za početnu tekućinu;
Here, for example, it can be a collecting table having downward cycles or the like. 
Ovdje, na primjer, to može biti stol za skupljanje koji ima napravu za cikličko spuštanje ili nešto tome slično.
The soft chewable veterinary composition of claim 1, wherein the pharmaceutically acceptable carrier comprises one or more fillers. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 1, naznačen time, da farmaceutski prihvatljiv nosač obuhvaća jedno ili više punila.
wherein A is as previously defined, m is 0, 1 or 2 and X is a leaving group, with a compound of the formula III 
II gdje A je kao prethodno definiran, m je 0, 1 ili 21 X je izlazeća skupina, sa spojem formule III HR P20080194 T3 du
The method according to paragraph 3, in which the initial dose is 0.1 mg/kg of rhASM. 
KSM za uporabu sukladno patentnom zahtjevu 2, pri čemu je inicijalna doza 0,1 mg/kg rhKSM.
The nucleotide or, nucleoside analogue reverse transcriptase inhibitor, comprised in the silica particles of the depot formulation of the present invention is, in some embodiments of the present invention, selected from the group consisting of zidovudine, didanosine, zalcitabine, stavudine, lamivudine abacavir, emtricitabine, entecavir, tenofovir, adefovir, apricitabine, elvucitabine, amdoxovir and racivir, preferably entecavir. 
Depo formulacija u skladu sa bilo kojim od prethodnih patentnih zahtjeva naznačena time da nukleotidni ili nukleozidni analog inhibitor reverzne transkriptaze je odabran od grupe koja se sastoji od - dideoksinukleozida, i/ili - zidovudina, didanozina, zalcitabina, stavudina, lamivudin abakavira, emtricitabina, entekavira, tenofovira, adefovira, apricitabina, elvucitabina, amdoksovira i racivira, poželjno entekavira.
In certain embodiments, the antibodies specifically bind to the extracellular domain of a human LGR protein. 
Izolirano monoklonalno protutijelo, naznačeno time, da se specifično veže na izvanstaničnu domenu od receptora
R, R1, R2 and R3 are the same or different and independently of each other chosen from hydrogen, (C1-C4)alkyl or CF3; 
R, Ri, R2 1 Rs su isti ili različiti i medusobno ih se neovisno bira izmedu vodika, (C;-Cg)alkila ili CF,;
forecasting of the industrial and civil consumptions for managing the storage of oils and refined products, and optimize the logistic of the service stations; 
– prognoziranja industrijske i kućne potrošnje radi upravljanja spremanjem nafte i njezinih derivata, i optimiziranja logistike benzinskih crpki;
A pharmaceutical composition according to claim 1, wherein the HDAC inhibitor is selected from the following compound and pharmaceutically acceptable salts thereof: 
(a) HDAC inhibitor, pri čemu je HDAC inhibitor spoj sa sljedećom formulom, ili njegov(a) farmaceutski prihvatljiva sol ili solvat: i
A therapeutically effective amount of the pharmaceutical composition according to any of claims 1 to 8 for use in the treatment of a cancer in a patient. 
Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 5, stanica u skladu s patentnim zahtjevom 8 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 11 za upotrebu u liječenju karcinoma.
The method as claimed in claim 1, wherein the cotton is selected from the group consisting of natural cotton, surgical cotton, clinical grade cotton, commercial cotton, spun cotton, water washed cotton, acid or base washed cotton, autoclaved cotton, buffer treated cotton having pH ranging from about 1 to about 14, salt solution treated cotton, organic solvent treated cotton, pressed cotton and processed cotton. 
Komplet u skladu s patentnim zahtjevom 11, naznačen time što se pamuk bira iz skupine koju čine prirodni pamuk, kirurški pamuk, pamuk kliničke kvalitete, komercijalni pamuk, predeni pamuk, pamuk pran vodom, pamuk pran kiselinom ili bazom, autoklavirani pamuk, puferirani pamuk s pH u rasponu od otprilike 1 do otprilike 14, pamuk obrađen otopinom soli, pamuk obrađen organskim otapalom, tiješteni pamuk i prerađeni pamuk.
an entropy decoder which determines coding units of a hierarchical structure by using information about whether to divide a coding unit parsed from a received bitstream; and 
određivanje kodirajućih jedinica hijerarhijske strukture pomoću uporabe informacija o tome treba li podijeliti kodirajuću jedinicu analiziranu iz primljene struje bita (bitstream);
The method of any one of claims 4 to 7, further comprising obtaining a cfDNA sample from the recipient following transplantation of donor tissue; and quantifying the level of the donor SNP allele in the cfDNA sample, optionally wherein 
Metoda prema bilo kojem patentnom zahtjevu od 4 do 7, koja se dodatno sastoji od uzimanja uzorka cfDNK od primatelja nakon presađivanja tkiva darivatelja; i kvantifikacije razine SNP alela darivatelja u uzorku cDNK, opcionalno naznačena time, što (i) korak kvantifikacije se sastoji od utvrđivanja broja preslike SNP alela darivatelja u uzorku cfDNK ili utvrđivanja postotka SNP alela darivatelja u uzorku cfDNK;